Moderna, Inc.
Moderna, Inc. (MRNA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mrna · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Moderna, Inc. (MRNA) measures how much investors pay for each dollar of the company's trailing earnings. MRNA's current PE ratio of N/A is calculated by dividing its stock price of $47.59 by its TTM earnings per share of -$8.09.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Moderna, Inc.You MRNA | $18.9B | N/A | — | -$8.09 |
 BridgeBio Pharma, Inc. BBIO | $13.3B | N/A | — | -$3.70 |
 BioMarin Pharmaceutical Inc. BMRN | $10.9B | 32.67x | +33.8% | $1.82 |
 Caris Life Sciences, Inc. CAI | $4.7B | N/A | — | -$0.32 |
 Exelixis, Inc. EXEL | $13.0B | 15.12x | -38.1% | $2.88 |
 Halozyme Therapeutics, Inc. HALO | $8.5B | 25.45x | +4.2% | $2.64 |
 Jazz Pharmaceuticals plc JAZZ | $14.7B | N/A | — | -$5.84 |
Industry Average 3 peers with valid PE | — | 24.41x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-7.25 | — | |
2024-12-31 FY2024 | — | $-9.27 | — | |
2023-12-31 FY2023 | — | $-12.34 | — | |
2022-12-31 FY2022 | 8.46x | $21.22 | +0.9% | |
2021-12-31 FY2021 | 8.39x | $30.28 | — | |
2020-12-31 FY2020 | — | $-1.96 | — | |
2019-12-31 FY2019 | — | $-1.55 | — | |
2018-12-31 FY2018 | — | $-1.17 | — | |
2017-12-31 FY2017 | — | $-0.68 | — | |
2016-12-31 FY2016 | — | $-3.37 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Moderna, Inc. (MRNA) measures how much investors pay for each dollar of the company's trailing earnings. MRNA's current PE ratio of N/A is calculated by dividing its stock price of $47.59 by its TTM earnings per share of -$8.09.
Frequently asked questions
MRNA pe ratio · 6 questionsMRNA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $47.59 and TTM EPS of -$8.09. Data sourced from Financial Modeling Prep via MRNA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Moderna, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08